Antibodies against the myelin oligodendrocyte glycoprotein and the myelin basic protein in multiple sclerosis and other neurological diseases: a comparative study

Citation
M. Reindl et al., Antibodies against the myelin oligodendrocyte glycoprotein and the myelin basic protein in multiple sclerosis and other neurological diseases: a comparative study, BRAIN, 122, 1999, pp. 2047-2056
Citations number
50
Categorie Soggetti
Neurology,"Neurosciences & Behavoir
Journal title
BRAIN
ISSN journal
00068950 → ACNP
Volume
122
Year of publication
1999
Part
11
Pages
2047 - 2056
Database
ISI
SICI code
0006-8950(199911)122:<2047:AATMOG>2.0.ZU;2-M
Abstract
In experimental animal models of multiple sclerosis demyelinating antibody responses are directed against the myelin oligodendrocyte glycoprotein (MOG ). We have investigated whether a similar antibody response is also present in multiple sclerosis patients. Using the recombinant human extracellular immunoglobulin domain of MOG (MOG-Ig) we have screened the sera and CSFs of 130 multiple sclerosis patients, 32 patients with other inflammatory neuro logical diseases (OIND), 30 patients with other non-inflammatory neurologic al diseases (ONND) and 10 patients with rheumatoid arthritis. We report tha t 38 % of multiple sclerosis patients are seropositive for IgG antibodies t o MOG-Ig compared with 28 % seropositive for anti-myelin basic protein (MBP ). In contrast, OIND are characterized by similar frequencies of serum IgG antibody responses to MOG-Ig (53 %) and MBP (47 %), whereas serum IgG respo nses to MOG-Ig are rare in ONND (3 %) and rheumatoid arthritis (10 %). Anti -MBP IgG antibodies, however, are a frequent finding in ONND (23 %) and rhe umatoid arthritis (60 %). Our results provide clear evidence that anti-MOG- Ig antibodies are common in CNS inflammation. However, in OIND these antibo dy responses are transient, whereas they persist in multiple sclerosis. We demonstrate that the serum anti-MOG-Ig response is already established in e arly multiple sclerosis (multiple sclerosis-R0; 36 %). In later multiple sc lerosis stages frequencies and titres are comparable with early multiple sc lerosis. In contrast, the frequency of anti-MBP antibodies is low in multip le sclerosis-R0 (12 %) and increases during disease progression in relapsin g-remitting (32 %) and chronic progressive multiple sclerosis (40 %), thus suggesting that anti-MBP responses accumulate over time. Finally we provide evidence for intrathecal synthesis of IgG antibodies to MOG-Ig in multiple sclerosis.